Pleural Dynamics secures FDA clearance for ACES effusion shunt system

2023-10-20
The ACES system is intended to provide continuous symptom alleviation, and doesn't require costly drainage canisters, longer hospital stay, or a catheter external to the chest FDA approves Pleural Dynamics’ ACES system. (Credit: kalhh from Pixabay) American medical device firm Pleural Dynamics has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its new ACES Automatic Continuous Effusion Shunt System. The ACES system is intended to provide continuous symptom alleviation and doesn’t require costly drainage canisters, longer hospital stay, or a catheter external to the chest. The Minnesota-based Pleural Dynamics is said to be the first and only company to provide a fully implantable automatic effusion shunt that is driven by normal breathing. Dartmouth-Hitchcock Medical Center pulmonary and critical care medicine chief David Feller-Kopman said: “ACES focuses on patient-centered outcomes, potentially eliminating the need for a long hospital stay and chronic drainage at home. This is a potentially perfect solution.” Pleurodesis, which is the current standard of care, is frequently painful and necessitates an extended hospital stay, said Pleural Dynamics. The one-piece, completely implanted ACES system from the company can be implanted during a brief hospital stay and is said to address these shortcomings. Pleural Dynamics’ technology utilises natural breathing movements to automatically transfer pleural effusion fluid from the chest to the abdomen, where it can be reabsorbed by the body. This eliminates the necessity for an external catheter and the frequent need for drainage, thereby ensuring continuous symptom relief. The company will now start real-world clinical use of the ACES system with a few hospitals and health systems. It also anticipates that the technology will significantly enhance the quality of life for people with intractable pleural effusion.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
靶点
-
药物
-
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI,赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台,以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。